Loading
A phase 2/3 trial testing HR070803 in colorectal cancer, active and no longer recruiting.
A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer is a phase 2/3 interventional study registered as NCT05945901, led by Jiangsu HengRui Medicine, and active but no longer recruiting on the registry. Official title: A Phase II/III, Double-blind, Randomised, Multi-centre Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer. Planned enrolment is 669 participants (actual). The study started in 2023-08-14 and primary completion is expected in 2025-12-01. No results have been posted on ClinicalTrials.gov.
Shares HR070803, Colorectal cancer.